Latest Industry Insights
Advanced Cell Screening and Imaging Reveals How the Cardiac System Responds in Drug Development
In drug discovery, time and monetary investments increase significantly the further candidates advance through the preclinical phase of testing, analysis and evaluation. By excluding non-viable compounds for safety and toxicity reasons early on, resources can be redirected to bring the most promising drugs to market sooner.
Pushing the Boundaries of Translational Molecular Imaging
Professor Ron Heeren recently embarked on a study to bring together the spatial molecular information that is provided by MALDI-MSI with the microproteomic characterization generated by LC-MS on the same tissue specimen, on a single instrument. Heeren and colleagues were successful in this feat. Their work is published in the journal Proteomics and forms the basis of this interview.
Engineering Innovative CAR T-Cell Therapy Candidates for Cancer
Technology Networks recently had the pleasure of speaking with Celyad Oncology’s CEO Filippo Petti. In this interview, Petti discusses key immunotherapy advances, highlights the two main CAR T-cell therapy approaches and elaborates on the company’s “off-the-shelf” CAR T cells.
Next-Generation Sequencing: Tracking the Spread and Evolution of SARS-CoV-2
This article explores how next-generation sequencing (NGS) is being used to help track the spread and evolution of SARS-CoV-2, including pinpoint the different lineages of the virus and identifying patterns of its movement both globally as well as locally.
A Smarter Way To Remove Host Cell Protein Contamination From Gene Therapies
In this piece, Ejvind Mørtz and Todd Stawicki explain why it’s critical that gene therapy products are free of host cell proteins and how this can be ensured in the production process, so that these next-generation drugs can fulfil their potential as one-shot cures for a range of diseases, from rare genetic conditions to cancer.
A Conversation With Professor Josef Penninger on the Journey to a COVID-19 Therapeutic
The ACE2 receptor has garnered significant attention for the wrong reasons over recent months. Could it point towards an exit route out of this pandemic? In an interview with Technology Networks, the renowned immunologist Professor Josef Penninger explains why he thinks so, and discusses the latest clinical data obtained from testing the soluble ACE2 receptor, APN01.
Using Organoids in the Study of Infectious Diseases
By providing greater physiologic relevance and a species- or patient-specific test platform, organoids overcome many limitations of conventional 2D cultures and even live-animal disease models.
Tapping Into Information Locked in Our T Cells To Fight COVID-19
T cells are an important part of our immune memory and offer a wealth of valuable information about the way our bodies perceive and respond to pathogens. Learn how this information is being harnessed and applied in the fight against COVID-19.
Harnessing Human Skin Models for Drug Development
We recently spoke with Pascal Descargues, CEO at Genoskin to learn more about the legal restrictions on animal testing and how human skin tissue can be used as an alternative.
Breaking Down Barriers in Proteomic-Based Drug Discovery
SomaLogic recently announced an agreement with the biopharmaceutical company Amgen that aims to advance Amgen's drug discovery and development programs through comprehensive proteomic profiling. We spoke with Roy Smythe to discover what barriers have been holding proteome analysis back, and how the collaboration with Amgen aims to change the landscape of drug discovery.